AbbVie Inc.
ABBV
Unten findest du den Live-Kurs für AbbVie Inc. (ABBV), einen 1-Jahres-Chart, 8 Indikatoren (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volumen) und einen Vergleichsmodus. Hinzufügen zum Portfolio, auf die Beobachtungsliste setzen oder einen Preisalarm einrichten — alles in einem.
AbbVie Inc. (ABBV) ist ein in United States ansässiges Healthcare-Unternehmen. Tätig in der Branche Drug Manufacturers - General, beschäftigt rund 57,000 Mitarbeiter:innen. Im vergangenen Jahr bewegte sich ABBV zwischen 184.63 und 261.64 USD. Das Trailing-KGV liegt bei rund 124.75, die Marktkapitalisierung bei etwa 449.63B USD. Aktuell wirft die Aktie eine Dividendenrendite von 2.72 % ab.
- Prev close
- $254.39
- Volume (24h)
- $1.33B
- Market cap
- $449.63B
- Currency
- USD
Bewertung
42/ 100 · Schwach
- Wert50
- Qualität66
- Momentum58
- Wachstum23
- Risiko73
- Dividende17
- Liquidität9
Komposit aus öffentlichen Marktdaten. Nur zur Information — keine Anlageberatung.
Trendprojektion
Wohin der jüngste Trend zeigt, wenn er sich fortsetzt.
- +5 Bars
- 258.9941 +1.77%
- +20 Bars
- 265.3399 +4.26%
- +60 Bars
- 267.8363 +5.24%
- +120 Bars
- 267.9283 +5.28%
Lineare Regressions-Fortschreibung — keine Vorhersage, keine Anlageberatung. ±1σ ≈ 68% · ±2σ ≈ 95%: ±0.0275 USD.
Interpretation
Die zusammengesetzten Signale wirken schwach. Stärke: Risikoprofil mit schwäche: bilanzliquidität. Kurs liegt im oberen Drittel der jüngsten Spanne, Trend zeigt nach oben.
Beschreibende Beobachtung — keine Anlageberatung.
Bewertungs-Aufschlüsselung
Die Rohwerte hinter jedem Pillar — so siehst du, was die zusammengesetzte Bewertung liest.
- Wert50/100
Wert wirkt gemischt — getragen von KGV (124.75).
KGV:124.75PEG:0.42 - Qualität66/100
Qualität wirkt solide — getragen von Bruttomarge (72.03%).
GK-Rendite:10.03%Nettomarge:5.79%Bruttomarge:72.03% - Momentum58/100
Momentum wirkt gemischt — getragen von 52-Wo. Veränderung (37.67%).
52-Wo. Veränderung:37.67% - Wachstum23/100
Wachstum wirkt fragil — getragen von EPS-Wachstum (-46.20%).
Umsatzwachstum:12.40%EPS-Wachstum:-46.20% - Risiko73/100
Risiko wirkt solide — getragen von Beta (0.28).
Beta:0.28Leerverkaufsquote:1.38% - Dividende17/100
Dividende wirkt fragil — getragen von Ausschüttungsquote (325.98%).
Dividendenrendite:2.72%Ausschüttungsquote:325.98% - Liquidität9/100
Liquidität wirkt fragil — getragen von Liquidität 3. Grades (0.8).
Liquidität 3. Grades:0.8Liquidität 2. Grades:0.52
Abgeleitet aus öffentlichen Marktdaten — informativ, keine Anlageberatung.
Referenzniveaus
Fibonacci-Retracements und -Extensions im jüngsten Bereich.
Nur Referenz — keine Anlageberatung.
Diese Koordinaten beschreiben Preisballungen aus der Vergangenheit, nicht wo gekauft oder verkauft werden sollte. Recherchiere selbst, bevor du handelst.
- ResistanceFib-Extension +161.8%376.3401 USD+47.88% vom aktuellen Kurs
- ResistanceFib-Extension +100%332.53 USD+30.67% vom aktuellen Kurs
- ResistanceFib-Extension +61.8%305.45 USD+20.02% vom aktuellen Kurs
- ResistanceFib-Extension +27.2%280.9221 USD+10.39% vom aktuellen Kurs
- Aktuell254.49 USD
- SupportFib-Retracement 23.6%244.91 USD-3.76% vom aktuellen Kurs
- SupportFib-Retracement 38.2%234.56 USD-7.83% vom aktuellen Kurs
- SupportFib 50% Mittelpunkt226.195 USD-11.12% vom aktuellen Kurs
- SupportFib-Retracement 61.8%217.83 USD-14.41% vom aktuellen Kurs
- SupportFib-Retracement 78.6%205.9205 USD-19.09% vom aktuellen Kurs
- SupportFib-Extension −27.2%171.4679 USD-32.62% vom aktuellen Kurs
- SupportFib-Extension −61.8%146.94 USD-42.26% vom aktuellen Kurs
- SupportFib-Extension −100%119.86 USD-52.90% vom aktuellen Kurs
Financials
- 52w high
- $261.64
- 52w low
- $184.63
- 52w change
- 37.67%
- Day high
- $260.84
- Day low
- $254.29
- P/E (TTM)
- 124.75
- Forward P/E
- 15.63
- PEG
- 0.42
- Beta (5Y)
- 0.28
- Enterprise value
- 513.2B
- EV / Revenue
- 8.17
- EV / EBITDA
- 17.16
- EPS (TTM)
- $2.04
- Forward EPS
- $16.28
- Dividend yield
- 2.72%
- Dividend rate
- $6.92
- Payout ratio
- 325.98%
- Revenue (TTM)
- 62.82B
- EBITDA
- 29.92B
- Free cash flow
- 20.81B
- Total cash
- 9.39B
- Total debt
- 72.91B
- Current ratio
- 0.8
- Quick ratio
- 0.52
- Profit margin
- 5.79%
- Gross margin
- 72.03%
- Return on assets
- 10.03%
- Shares outstanding
- 1.77B
- Float
- 1.76B
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.28
- very stable
- 52-week change
- 37.67%
- Short % of float
- 1.38%
- Short ratio (days)
- 2.52
- Current ratio
- 0.8
- Quick ratio
- 0.52
- ROA
- 10.03%
- PEG ratio
- 0.42
- potentially undervalued
- EV / Revenue
- 8.17
- EV / EBITDA
- 17.16
- Revenue growth
- 12.40%
- Earnings growth
- -46.20%
- EBITDA
- 29.92B
- Free cash flow
- 20.81B
- Total cash
- 9.39B
- Total debt
- 72.91B
- Insider holdings
- 0.11%
- Institutional
- 76.86%
Recent rating changes
- 2026-07-15CitigroupNeutral → Neutralmain
- 2026-07-13UBSNeutral → Neutralmain
- 2026-07-13BMO CapitalOutperform → Outperformmain
- 2026-07-10B of A SecuritiesBuy → Buymain
- 2026-07-10RBC CapitalOutperform → Outperformmain
- 2026-07-10Wells FargoOverweight → Overweightmain
- 2026-07-09GuggenheimBuy → Buymain
- 2026-07-09JP MorganOverweight → Overweightmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-07-06
- Annual report of employee stock purchase11-K2026-06-24
- Corporate Changes & Voting Matters8-K2026-06-22
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-06-01
- Corporate Changes & Voting Matters8-K2026-05-12
- Periodic Financial Reports10-Q2026-05-08
- Corporate Changes & Voting Matters8-K2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-03
- Proxy StatementsDEFA14A2026-03-23
- Proxy StatementsPRE 14A2026-03-09
- Corporate Changes & Voting Matters8-K2026-03-04
- Periodic Financial Reports10-K2026-02-20
Aktuelle Nachrichten
- How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?Motley Fool8h ago
- What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.Barrons.com3h ago
- My 2 Favorite Dividend Kings to Buy Right NowMotley Fool13h ago
- 3 Biggest Pharma Giants: Buy, Sell or Hold?24/7 Wall St.20h ago
- REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingPR Newswire1d ago
- IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?Motley Fool1d ago
- AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In EuropeSimply Wall St.2d ago
- IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?Motley Fool1d ago
Verwandt
Weitere Assets in dieser Kategorie.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live-Diskussion
Anmelden to join the discussion.
- Noch keine Kommentare. Sei der Erste.